UnitedHealth Group Inc vs GeneDx Holdings Corp — how do they compare? UnitedHealth Group Inc trades at $405.6 (market cap $361.00B), while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: UnitedHealth Group Inc is far larger — about 148× GeneDx Holdings Corp's market cap, and UnitedHealth Group Inc pays a 2.31% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| UNH | WGS | |
|---|---|---|
Market Cap | $361.00B | $2.44B |
Sector | Health | Technology |
52-Week High | $436.35 | $167.51 |
52-Week Low | $259.02 | $34.51 |
Enterprise Value | $402.86B | $2.48B |
Dividend Yield | 2.31% | — |
Signals from Pluang's Aura AI — not financial advice
UnitedHealth Group (UNH) trades at $408.74, showing modest daily gains of 0.41% amid a bearish technical signal. The company demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust analyst support (82.7% buy ratings). Recent developments include dividend payments and strategic initiatives to streamline pediatric care authorizations, positioning UNH well in the healthcare sector.
UNH presents a compelling investment case with strong cash flow generation and market leadership, though investors face risks from regulatory scrutiny and margin compression. The stock trades at a discount to analyst consensus target of $476.50, offering potential upside if operational improvements and growth initiatives materialize as projected.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Trailing returns across standard periods
Latest headlines on both assets
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →